<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104010</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 034 CT</org_study_id>
    <nct_id>NCT03104010</nct_id>
  </id_info>
  <brief_title>A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD</brief_title>
  <official_title>A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of Adult Growth Hormone Deficiency (AGHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Three Gorges Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the optimal dose of PEG-rhGH injection in the treatment of AGHD,&#xD;
      preliminarily evaluate its safety and efficacy, to provide scientific and reliable evidence&#xD;
      for the medication dosage in Phase 2 clinical study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat mass change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in fat mass (torso) (FM): FM at the end of treatment minus the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean body mass change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in lean body mass (LBM): LBM at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in blood lipid: blood lipid at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in waist circumference: waist circumference at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of body fat change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in the percentage of body fat: TBF at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac function: ejection fraction at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac structure change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac structure: left ventricular mass at the end of treatment minus the baselines value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in IGF-1: IGF-1 SDS at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in grip: grip at the end of treatment minus the baseline value, the method of assessment is measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in quality of life (QOL): changes in QOL scores before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-hip ratio change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in waist-hip ratio: changes of waist-hip ratio before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac structure change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac structure: carotid intima media thickness at the end of treatment minus the baselines value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>PEG-rhGH-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rhGH-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin Injection</intervention_name>
    <description>Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.</description>
    <arm_group_label>PEG-rhGH-1</arm_group_label>
    <arm_group_label>PEG-rhGH-2</arm_group_label>
    <other_name>Recombinant human growth hormone injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Before the treatment, the subject should be diagnosed as AGHD based on medical&#xD;
             history, clinical symptoms, vital signs, insulin tolerance test and imagological&#xD;
             examinations.&#xD;
&#xD;
               -  The subject is diagnosed as GHD during childhood and remains as GHD in adulthood,&#xD;
                  and the linear growth has completed: bone age (BA) ≥18 years old; or the AGHD&#xD;
                  patient who experiences paroxysm after 18 years old: such as patients who have&#xD;
                  experienced pituitary surgeries (2 years after pituitary adenoma surgery, 5 years&#xD;
                  after craniopharyngioma surgery and 12 months after other pituitary surgeries),&#xD;
                  traumatic brain injury (TBI), Sheehan syndrome, and etc..&#xD;
&#xD;
               -  The plasma GH concentration peak is &lt;5ng/ml in insulin tolerance test (ITT) (it's&#xD;
                  unnecessary to conduct ITT in the following conditions: anterior pituitary&#xD;
                  dysfunction, pituitary hormone deficiency (more than 3 hormones) and serum IGF-1&#xD;
                  level below lower limit of normal value: i.e. -2 SD).&#xD;
&#xD;
          -  Age: 18-60 years old.&#xD;
&#xD;
          -  Patients with no history of GH treatment for more than one year.&#xD;
&#xD;
          -  Body mass index (BMI): 18.5 kg/m2≤BMI≤30kg/m2.&#xD;
&#xD;
          -  When there is other hormones deficiency (such as glucocorticoids, thyroid hormones and&#xD;
             sex steroids), the subject should have received other hormone replacement therapies&#xD;
             and the therapeutic dose shall be stable within 3 months before the enrolment.&#xD;
&#xD;
          -  The subject agrees to cooperate and complete the concerted trial procedures such as&#xD;
             follow-ups, treatment plan and laboratory examinations, and sign the written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with serious heart diseases, including NYHA III or above, serious arrhythmia,&#xD;
             unstable angina pectoris or myocardial infarction within the latest 6 months.&#xD;
&#xD;
          -  Patients with a history of ischemic cerebrovascular disease, febrile convulsion and&#xD;
             epilepsy seizures.&#xD;
&#xD;
          -  Patients with carpal tunnel syndrome.&#xD;
&#xD;
          -  Patients with poor hypertension control (systolic pressure&gt;140mmHg or diastolic&#xD;
             pressure &gt;90mmHg under treatment).&#xD;
&#xD;
          -  Patients with previous or present history of malignant tumor: two or more direct&#xD;
             relatives within three generations have previous or present history of tumor.&#xD;
&#xD;
          -  Patients undergoing anti-depressive therapy, immunosuppressive therapy, chemotherapy&#xD;
             and radiotherapy (or with a history of radiotherapy).&#xD;
&#xD;
          -  Patients who have ever taken antiobesity drug within the latest 3 months.&#xD;
&#xD;
          -  Patients with serious infection.&#xD;
&#xD;
          -  Patients with consciousness disorders and mental diseases.&#xD;
&#xD;
          -  Subjects with impaired glucose regulation (IGR) (impaired fasting glucose (IFG) and/or&#xD;
             impaired glucose tolerance (IGT) ) or diabetes; patients with a family history of&#xD;
             diabetes (direct relatives).&#xD;
&#xD;
          -  Subjects with abnormal liver and kidney functions (ALT &gt; 2 times of upper limit of&#xD;
             normal value; eGFR calculated by MDRD formula &lt;60).&#xD;
&#xD;
          -  Subjects positive for anti-HBc, HBsAg or HBeAg in Hepatitis B virus tests.&#xD;
&#xD;
          -  Subjects with highly allergic constitution or allergy to proteins or investigational&#xD;
             productorits excipient in this study.&#xD;
&#xD;
          -  Subjects who took part in other clinical trials within 3 months.&#xD;
&#xD;
          -  Patients with other mental or physical deficiencies that influence the evaluation of&#xD;
             investigational product.&#xD;
&#xD;
          -  Pregnant or lactating women; females planning to get pregnant within one year.&#xD;
&#xD;
          -  Subjects whose tumor markers exceed the upper limit of normal range and the&#xD;
             re-examination result is still high.&#xD;
&#xD;
          -  Other conditions which is unsuitable for the study in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Pan, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Feng, MD</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Songjun Zhang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heibei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050057</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated hospital of soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Jiang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenmei An, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Gu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Pan, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Luo, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Ren, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

